Earnings Call · Q3 FY2023·2023-11-02

Q3 23EPS +32.84%·Rev n/aQ2 23EPS -43.40%·Rev n/aQ1 23EPS -47.73%·Rev n/aQ4 22EPS 0.00%·Rev n/a⚠ consensus missing

Definium Therapeutics, Inc. DFTX

Robert Barrow — CEO

Schond Greenway — Chief Financial Officer

+14.4%1d on move date+13.5% vs SPY3d+4.4%5d−5.9%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more DFTX calls or request research access.

More DFTX calls Browse calls Request research access